About the Network

The mission of the GErman NEtwork for Research on AuToimmune Encephalitis (GENERATE) is to empower cooperation between centers with clinical and scientific expertise. GENERATE we will enable us to better characterize the immunopathogenesis and neuropathophysiology of the different autoimmune encephalitides while elucidating the clinical particulars, clinical courses and treatment strategies. Owing to the rare occurrence of autoimmune encephalitis and other autoimmune inflammations of the brain, new evidence on incidences, clinical symptoms, risks, prognostic factors and efficacious treatments can only be amassed by collecting data on large numbers of cases.

The members of the Network pursue the following mutual clinical and scientific objectives:

  • Setting up a joint patient register to standardize clinical data collection
  • Building a biobank with cells, blood & CSF for later analysis
  • Creating a joint brain biopsy database
  • Evaluating the pathogenicity of antineuronal antibodies
  • Developing diagnostic and therapeutic standards and assessing national and international treatment recommendations
  • Providing help in therapeutic decision-making, directing affected individuals and their relatives to qualified counseling services
  • Conducting prospective studies on the therapy and clinical course of autoimmune encephalitis
  • Liaison work between patients interested in clinical trials and the competent centers (e.g. MRI, therapy or prognosis studies)

Dear Colleagues,
Please take part in the initiative…

The Network cannot achieve its mission unless its many stakeholders work collaboratively. Therefore, we call upon all interested members of the medical community to impart to us their own experiences with their patients.

If you would like your center to participate in the clinical trials task force, don't hesitate to contact us by email at: info@generate-net.de or by using the contact form.


Find a center near you here.

Latest news

Sechste Fallkonferenz GENERATE & NEMOS

Thema: Patienten mit AQP4-IgG-positiver NMOSD und Neudiagnose einer malignen hämatologischen Erkrankung unter Immuntherapie mit Azathioprin.

Montag, den 22.05.2023, 14:00 Uhr.

15. GENERATE e.V. Netzwerktreffen im Rahmen der DGN 2022

Mittwoch, den 02.11.2022, von 18.00 bis 19.30 Uhr im CityCube Berlin


June 26th to 29th 2022 | Tutzing, Germany

Upcoming events

Currently there are no events.


Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABAA receptor encephalitis

Brändle SM, Cerina M, Weber S et al. PNAS March 2, 2021 118 (9) e1916337118.

Dieses Paper wurde vom Research4Rare Verbund zum Paper of the Month gewählt und erscheint im April dieses Jahres im BMBF Newsletter!

A Therapeutic Non-self-reactive
SARS-CoV-2 Antibody
Protects from Lung Pathology
in a COVID-19 Hamster Model

Kreye J, Momsen Reincke S, Kornau HC et al.
Cell. 2020 Nov 12;183(4):1058-1069.e19.

CD8+ T-Lymphocyte–Driven Limbic
Encephalitis Results in Temporal Lobe

Pitsch J, van Loo KMJ, Gallus M et al.
Ann Neurol. 2021; 00:1-20.

Low CSF CD4/CD8+ T-cell proportions are associated with blood-CSF barrier dysfunction in limbic encephalitis.

Hansen N, Schwing K, Önder D, et al. Epilepsy Behav. 2020;102:106682.

An expanded parenchymal CD8+ T cell clone in GABAA receptor encephalitis.

Bracher A, Alcalá C, Ferrer J, et al. Ann Clin Transl Neurol. 2020;7(2):239‐244.

Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome

Bien CG, Bien CI, Dogan Onugoren M, et al. [published online ahead of print, 2020 Apr 3] [published correction appears in J Neurol. 2020 May 12;:]. J Neurol. 2020;10.1007/s00415-020-09814-3.

Support Group Autoimmunenzephalitis: